Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
43
IVVD Quote, Financials, Valuation and Earnings
Last price:
$1.61
Seasonality move
:
-42.22%
Day range:
$1.55 - $1.63
52-week range:
$0.46 - $3.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.26x
P/B ratio:
4.03x
Volume:
1.3M
Avg. volume:
3.1M
1-year change:
-9.04%
Market cap:
$375.3M
Revenue:
$25.4M
EPS (TTM):
-$0.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IVVD
Invivyd, Inc.
|
$15.5M | -$0.10 | 49.95% | -35.02% | $10.00 |
|
ACLX
Arcellx, Inc.
|
$13.4M | -$1.05 | -17.12% | -2.29% | $110.43 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 31.89% | 267.32% | $14.50 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $9.61 |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -- | -- | -- | $9.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IVVD
Invivyd, Inc.
|
$1.61 | $10.00 | $375.3M | -- | $0.00 | 0% | 4.26x |
|
ACLX
Arcellx, Inc.
|
$113.75 | $110.43 | $6.6B | -- | $0.00 | 0% | 176.15x |
|
ADMA
ADMA Biologics, Inc.
|
$16.29 | $25.67 | $3.9B | 19.13x | $0.00 | 0% | 8.20x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.36 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.00x |
|
MNKD
MannKind Corp.
|
$5.57 | $9.61 | $1.7B | 59.13x | $0.00 | 0% | 5.48x |
|
RLMD
Relmada Therapeutics, Inc.
|
$4.03 | $9.67 | $295.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IVVD
Invivyd, Inc.
|
2.8% | -0.370 | 1.14% | 2.13x |
|
ACLX
Arcellx, Inc.
|
10.52% | 0.923 | 1.09% | 3.90x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
FOLD
Amicus Therapeutics, Inc.
|
61.73% | -0.293 | 10.04% | 1.72x |
|
MNKD
MannKind Corp.
|
124.56% | -0.068 | 13.7% | 2.54x |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | 6.678 | -- | 2.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IVVD
Invivyd, Inc.
|
$11.6M | -$11M | -85.47% | -87.85% | -83.96% | -$8.3M |
|
ACLX
Arcellx, Inc.
|
$3.1M | -$61.8M | -44.21% | -49.8% | -1248.25% | -$49.5M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
FOLD
Amicus Therapeutics, Inc.
|
$156.8M | $15.9M | -4.09% | -12.36% | 8.61% | $16M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -$10.3M | -214.4% | -214.4% | -- | -$6.7M |
Invivyd, Inc. vs. Competitors
-
Which has Higher Returns IVVD or ACLX?
Arcellx, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of -1127.12%. Invivyd, Inc.'s return on equity of -87.85% beat Arcellx, Inc.'s return on equity of -49.8%.
Company Gross Margin Earnings Per Share Invested Capital IVVDInvivyd, Inc.88.43% -$0.06 $95.7M ACLXArcellx, Inc.62.76% -$0.99 $492.6M -
What do Analysts Say About IVVD or ACLX?
Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 521.12%. On the other hand Arcellx, Inc. has an analysts' consensus of $110.43 which suggests that it could fall by -2.92%. Given that Invivyd, Inc. has higher upside potential than Arcellx, Inc., analysts believe Invivyd, Inc. is more attractive than Arcellx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVVDInvivyd, Inc.3 1 0 ACLXArcellx, Inc.7 11 0 -
Is IVVD or ACLX More Risky?
Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arcellx, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IVVD or ACLX?
Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcellx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. Arcellx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVVD or ACLX?
Invivyd, Inc. quarterly revenues are $13.1M, which are larger than Arcellx, Inc. quarterly revenues of $4.9M. Invivyd, Inc.'s net income of -$10.5M is higher than Arcellx, Inc.'s net income of -$55.8M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while Arcellx, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 4.26x versus 176.15x for Arcellx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVVDInvivyd, Inc.4.26x -- $13.1M -$10.5M ACLXArcellx, Inc.176.15x -- $4.9M -$55.8M
-
Which has Higher Returns IVVD or ADMA?
ADMA Biologics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of 27.14%. Invivyd, Inc.'s return on equity of -87.85% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital IVVDInvivyd, Inc.88.43% -$0.06 $95.7M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About IVVD or ADMA?
Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 521.12%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 57.56%. Given that Invivyd, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Invivyd, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVVDInvivyd, Inc.3 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is IVVD or ADMA More Risky?
Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.
-
Which is a Better Dividend Stock IVVD or ADMA?
Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVVD or ADMA?
Invivyd, Inc. quarterly revenues are $13.1M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Invivyd, Inc.'s net income of -$10.5M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 19.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 4.26x versus 8.20x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVVDInvivyd, Inc.4.26x -- $13.1M -$10.5M ADMAADMA Biologics, Inc.8.20x 19.13x $134.2M $36.4M
-
Which has Higher Returns IVVD or FOLD?
Amicus Therapeutics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of 0.91%. Invivyd, Inc.'s return on equity of -87.85% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.
Company Gross Margin Earnings Per Share Invested Capital IVVDInvivyd, Inc.88.43% -$0.06 $95.7M FOLDAmicus Therapeutics, Inc.84.64% $0.01 $716.6M -
What do Analysts Say About IVVD or FOLD?
Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 521.12%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.98%. Given that Invivyd, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Invivyd, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVVDInvivyd, Inc.3 1 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is IVVD or FOLD More Risky?
Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock IVVD or FOLD?
Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVVD or FOLD?
Invivyd, Inc. quarterly revenues are $13.1M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Invivyd, Inc.'s net income of -$10.5M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 4.26x versus 7.00x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVVDInvivyd, Inc.4.26x -- $13.1M -$10.5M FOLDAmicus Therapeutics, Inc.7.00x -- $185.2M $1.7M
-
Which has Higher Returns IVVD or MNKD?
MannKind Corp. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of 9.72%. Invivyd, Inc.'s return on equity of -87.85% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IVVDInvivyd, Inc.88.43% -$0.06 $95.7M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About IVVD or MNKD?
Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 521.12%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 72.55%. Given that Invivyd, Inc. has higher upside potential than MannKind Corp., analysts believe Invivyd, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings IVVDInvivyd, Inc.3 1 0 MNKDMannKind Corp.8 0 0 -
Is IVVD or MNKD More Risky?
Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.131%.
-
Which is a Better Dividend Stock IVVD or MNKD?
Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVVD or MNKD?
Invivyd, Inc. quarterly revenues are $13.1M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Invivyd, Inc.'s net income of -$10.5M is lower than MannKind Corp.'s net income of $8M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 59.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 4.26x versus 5.48x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVVDInvivyd, Inc.4.26x -- $13.1M -$10.5M MNKDMannKind Corp.5.48x 59.13x $82.1M $8M
-
Which has Higher Returns IVVD or RLMD?
Relmada Therapeutics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of --. Invivyd, Inc.'s return on equity of -87.85% beat Relmada Therapeutics, Inc.'s return on equity of -214.4%.
Company Gross Margin Earnings Per Share Invested Capital IVVDInvivyd, Inc.88.43% -$0.06 $95.7M RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M -
What do Analysts Say About IVVD or RLMD?
Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 521.12%. On the other hand Relmada Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 139.87%. Given that Invivyd, Inc. has higher upside potential than Relmada Therapeutics, Inc., analysts believe Invivyd, Inc. is more attractive than Relmada Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVVDInvivyd, Inc.3 1 0 RLMDRelmada Therapeutics, Inc.3 0 0 -
Is IVVD or RLMD More Risky?
Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Relmada Therapeutics, Inc. has a beta of 0.766, suggesting its less volatile than the S&P 500 by 23.406%.
-
Which is a Better Dividend Stock IVVD or RLMD?
Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. Relmada Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVVD or RLMD?
Invivyd, Inc. quarterly revenues are $13.1M, which are larger than Relmada Therapeutics, Inc. quarterly revenues of --. Invivyd, Inc.'s net income of -$10.5M is lower than Relmada Therapeutics, Inc.'s net income of -$10.1M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while Relmada Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 4.26x versus -- for Relmada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVVDInvivyd, Inc.4.26x -- $13.1M -$10.5M RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Sell
48
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
ACLX alert for Feb 24
Arcellx, Inc. [ACLX] is up 77.43% over the past day.
Buy
73
HYMC alert for Feb 24
Hycroft Mining Holding Corp. [HYMC] is up 2.34% over the past day.
Sell
39
SCL alert for Feb 24
Stepan Co. [SCL] is down 20.6% over the past day.
